61 results
S-8
EX-4.4
MRKR
Marker Therapeutics Inc
11 Aug 22
Registration of securities for employees
5:10pm
S-3
EX-4.6
MRKR
Marker Therapeutics Inc
Shelf registration
10 Aug 21
5:11pm
S-3
EX-4.3
MRKR
Marker Therapeutics Inc
Shelf registration
10 Aug 21
5:11pm
S-3
EX-4.7
MRKR
Marker Therapeutics Inc
Shelf registration
10 Aug 21
5:11pm
S-3
EX-4.5
MRKR
Marker Therapeutics Inc
Shelf registration
10 Aug 21
5:11pm
SC 13D/A
EX-4
rleuobsyyrw0qgquo
18 Jun 20
Marker Therapeutics / Eastern Capital ownership change
4:42pm
8-K
EX-4.1
oi1oa16
2 Mar 20
Marker Therapeutics and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $30 million
9:03am
SC 13D/A
EX-4
831ttmj85
20 Feb 20
Beneficial ownership report (amended)
4:24pm
SC 13D/A
EX-4
z9u1jkx8
8 Nov 18
Marker Therapeutics, Inc.
11:22am
8-A12B/A
EX-4.1
mi62uq lqo0
17 Oct 18
Registration of securities on exchange (amended)
4:00pm
8-K
EX-4.4
hih7pa1x
17 Oct 18
Tapimmune and Marker Therapeutics Announce Successful Closing of Previously Announced Merger and Financing
4:00pm
8-K
EX-4.2
c510yui0t1yj4h
8 Jun 18
TapImmune Announces Pricing of $70 Million Private Placement
9:21am
8-K
EX-4.1
poacy0w n4vu
8 Jun 18
TapImmune Announces Pricing of $70 Million Private Placement
9:21am
SC 13D/A
EX-4
8d2mzur
16 May 18
Tapimmune Inc.
5:14pm